Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results

Click here to go back to your search results.

Prostate Cancer treatment details. Chemotherapy. Hormone. Memorial Sloan-Kettering Cancer Center, New York, NY, United States

Survival: 20.2 months
Toxicity Grade: 5
Treatments: Chemotherapy
Country: United States
City/State/Province: New York, NY
Hospital: Memorial Sloan-Kettering Cancer Center
Journal: Link
Date: 6/2011

This phase III study involved men with castration-resistant prostate cancer. Patients were divided into two treatment groups. Group A consisted of 476 patients with a median age of 70.9 years. Group B had 477 patients with a median age of 70.4 years.

Group A was treated with the chemotherapy agent docetaxel and the steroid prednisone. Group B received docetaxel and the chemotherapy agent calcitriol.

Deaths not due to disease progression were reported for both groups (adverse event grade 5) but specific causes were not given. Grade 3 or higher deep vein thrombosis, anemia, fatigue, and neutropenia were reported.

The median overall survival was 20.2 months for group A and 17.8 months for group B.

This study was supported by Novacea, makers of DN-101 (calcitriol).

Correspondence: Dr. Howard I. Scher; email:

E-mail to a Friend Email Physician More Information